BlackRock
DRUG

BlackRock’s Bright Minds Biosciences DRUG Stock Holding History

BlackRock’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.2M Buy
686,184
+64,251
+10% +$5.05M ﹤0.01% 2695
2026
Q1 		$45.4M Buy
621,933
+227,890
+58% +$18.3M ﹤0.01% 2570
2025
Q4 		$30.8M Buy
394,043
+159,925
+68% +$10.7M ﹤0.01% 2823
2025
Q3 		$14.2M Buy
234,118
+24,441
+12% +$949K ﹤0.01% 3273
2025
Q2 		$5.47M Buy
209,677
+208,999
+30,826% +$6.27M ﹤0.01% 3730
2025
Q1 		$24.5K Buy
678
+677
+67,700% +$24.8K ﹤0.01% 5062
2024
Q4 		$36 Hold
1
– – ﹤0.01% 5364
2024
Q3 		$1 Hold
1
– – ﹤0.01% 5220
2024
Q2 		$1 Hold
1
– – ﹤0.01% 5275
2024
Q1 		$1 Hold
1
– – ﹤0.01% 5279
2023
Q4 		$1 Hold
1
– – ﹤0.01% 5371
2023
Q3 		$2 Sell
1
-2,359
-100% -$6.29K ﹤0.01% 5442
2023
Q2 		$6.73K Hold
2,360
– – ﹤0.01% 5284
2023
Q1 		$5.19K Hold
2,360
– – ﹤0.01% 5368
2022
Q4 		$8.73K Hold
2,360
– – ﹤0.01% 5480
2022
Q3 		$15K Hold
2,360
– – ﹤0.01% 5550
2022
Q2 		$9K Hold
2,360
– – ﹤0.01% 5636
2022
Q1 		$18K Buy
2,360
+1,126
+91% +$12.6K ﹤0.01% 5577
2021
Q4 		$20K Buy
+1,234
New +$27.5K ﹤0.01% 5538

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock's DRUG Position: Q2 2026 in Review

BlackRock increased its Bright Minds Biosciences (DRUG) stake by 10% in Q2 2026, buying an estimated $5.05M and bringing the position to 686,184 shares worth $48.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

BlackRock first reported a position in DRUG in Q4 2021 and has held it in 19 quarters since. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • BlackRock held 686,184 shares of Bright Minds Biosciences worth $48.2M as of Q2 2026.
  • BlackRock bought 64,251 Bright Minds Biosciences shares in Q2 2026, an estimated $5.05M.
  • Bright Minds Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2695 holding.
  • BlackRock first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 19 quarters since.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.